Reply to John T. Leppert and James D. Brooks’ Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146–54

Brandon A. Mahal; David D. Yang; Paul L. Nguyen

首页> 外文期刊>European urology >Reply to John T. Leppert and James D. Brooks’ Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146–54

【24h】

Reply to John T. Leppert and James D. Brooks’ Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146–54

机译：回复John T. Leppert和James D. Brooks'信给编辑Re：Brandon A. Mahal，David D. Yang，Natalie Q. Wang，等。低前列腺特异性抗原，高级前列腺癌的临床和基因组特征。 EUR UROL 2018; 74：146-54

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2018年第5期|共2页
作者
Brandon A. Mahal; David D. Yang; Paul L. Nguyen;
展开▼
作者单位

Harvard Radiation Oncology Program;

Harvard Medical School;

Harvard Medical School;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
入库时间 2022-08-20 02:54:46

相似文献

外文文献

1. Reply to John T. Leppert and James D. Brooks’ Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146–54 [J] . Brandon A. Mahal, David D. Yang, Paul L. Nguyen European urology . 2018,第5期

机译：回复John T. Leppert和James D. Brooks'信给编辑Re：Brandon A. Mahal，David D. Yang，Natalie Q. Wang，等。低前列腺特异性抗原，高级前列腺癌的临床和基因组特征。 EUR UROL 2018; 74：146-54
2. Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70 Examining (the Lack of) Evidence for Coding Errors in IS Staging of Testicular Cancer Patients in the National Cancer Database [J] . Seisen Thomas, Kamran Sophia C., Markt Sarah C., European urology . 2018,第4期

机译：答复到Aditya Bagrodia，Solomon Woldu，David F. Penson，Alexander Kutikov和Samuel D. Kaffenberger的信Re：Sophia C. Kamran，Thomas Seisen，Sarah C. Markt等人。临床阶段的当代治疗模式和结果是睾丸癌。 2018年欧洲乌尔乌尔; 73：262-70检查（缺乏）编码误差的证据是国家癌症数据库中睾丸癌患者的分期
3. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.' s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2 [J] . Korakianiti Evdokia European urology . 2019,第3期

机译：回复乔·奥沙里凡，达尼尔海因里奇，尼古拉斯D.詹姆斯等。致编辑的信Re：欧洲药物局的案件对镭r镭-223的改变，用于治疗转移性阉割的前列腺癌。 2019年欧元尿牛; 75：E51-2

Reply to John T. Leppert and James D. Brooks’ Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146–54

著录项

相似文献

相关主题

期刊订阅